Recce Pharmaceuticals wins Canadian patent for flagship anti-infectives Posted on November 23, 2023 by recce_com Recce Pharmaceuticals wins Canadian patent for flagship anti-infectives
Recce Pharmaceuticals doses first patients over 15 minutes in R327 UTI/urosepsis trial Posted on November 7, 2023 by recce_com Recce Pharmaceuticals doses first patients over 15 minutes in R327 UTI/urosepsis trial
Recce Pharmaceuticals completes dosing of first subjects at faster infusion rate in RECCE® 327 clinical trial Posted on November 7, 2023November 20, 2023 by recce_com Recce Pharmaceuticals completes dosing of first subjects at faster infusion rate in RECCE® 327 clinical trial
Recce Pharmaceuticals presents at Ord Minnett Healthcare Forum Posted on November 1, 2023November 20, 2023 by recce_com Recce Pharmaceuticals presents at Ord Minnett Healthcare Forum
Recce Pharma welcomes approval for faster RECCE327 infusion rate Posted on October 25, 2023November 20, 2023 by recce_com Recce Pharma welcomes approval for faster RECCE327 infusion rate
Recce Pharmaceuticals accelerates R327 trial for UTI patients with faster infusion rate approval Posted on October 24, 2023November 21, 2023 by recce_com Recce Pharmaceuticals accelerates R327 trial for UTI patients with faster infusion rate approval
Busiest quarter for Recce Pharmaceuticals: Cashed up for next phases of drug development Posted on October 23, 2023 by recce_com Busiest quarter for Recce Pharmaceuticals: Cashed up for next phases of drug development
Recce Pharma says commercial potential of its anti-infectives is gaining recognition Posted on October 11, 2023 by recce_com Recce Pharma says commercial potential of its anti-infectives is gaining recognition
Recce Pharmaceuticals raise to progress advanced anti-infective Posted on October 9, 2023November 21, 2023 by recce_com Recce Pharmaceuticals raise to progress advanced anti-infective
Global fund takes stake in Recce as synthetic antibiotic developer raises $11m Posted on October 6, 2023November 21, 2023 by recce_com Global fund takes stake in Recce as synthetic antibiotic developer raises $11m
